BioLineRx is trading 5.96% lower at $2.21 after hours, extending a weak stretch without a clear company-specific catalyst.

  • Shares closed at $2.35 in the September 30 regular session.
  • Shares fell 6.54% on September 28 and 2.88% on September 29.
  • No clear September 30 company-specific announcement was identified. The latest identified news concerned September GLIX1 presentations and a September 23 shareholder meeting; broad-market moves were mixed.